[Advert,fallback=]

Agreement / Collaboration / M&A HanchorBio and WuXi Biologics Enter Strategic Partnership to Advance Next-Generation Bi-and Multi-Functional Fusion Protein Pipeline MS Pharma Group Signs Exclusive Biosimilars Partnership Agreement with Hetero StarkAge Therapeutics Announces Research Collaboration with Gustave Roussy to Advance Senolytic Therapies in Digestive Cancers Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease Defence Therapeutics Expands Collaboration With Canadian Nuclear Laboratories To Accelerate Its Proprietary Radiopharmaceutical Pipeline Physiomics Awarded New Contract by Numab Therapeutic InSysBio to announce a new collaborative project with BeOne Medicines WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody Repare Announces Completion of Acquisition by XenoTherapeutics, Inc. Accent Therapeutics to Utilize Inocras’ CancerVision and MRDVision Platforms in Phase 1/2 ATX-295 Clinical Study Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA Immuto Scientific and University of Wisconsin–Madison Announce Collaboration to Advance Discovery of Novel Cancer Targets Illumina completes acquisition of SomaLogic Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender Offer Funding BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility Primmune Therapeutics Announces Additional Close of Series B Financing Fortitude Biomedicines Launches With $13M in Financing to Advance Novel Antibody-based Therapies for Treatment of Autoimmune Diseases and Cancer AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer Rakovina Therapeutics Announces Corporate Update Including up to $1.6 Million in New Financing, Leadership Appointments and Debt Restructuring Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock BridGene Biosciences Raises $28 Million in Series B+ Financing to Accelerate Clinical Development of BGC-515 and Platform Expansion Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules CraniUS Therapeutics Closes $20 Million Series B Round to Advance NeuroPASS Platform Towards Future Commercialization Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility LEXICON ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock ALX Oncology Announces Pricing of Underwritten Offering Submission / Acceptance / Opinion / Approval Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma Chugai Files for Additional Indication of Tecentriq for the Treatment of Adjuvant Therapy for MRD-Positive Bladder Cancer DARZALEX FASPRO-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible Elevar Therapeutics Submits New Drug Application to FDA for Lirafugratinib as Second-Line Treatment Option for Cholangiocarcinoma Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201 Shorla Oncology Announces U.S. FDA Approval of Larger Vial Size for Nelarabine Intravenous Administration for the Treatment of T-cell Acute Lymphoblastic Leukemia and T-cell Lymphoblastic Lymphoma Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy Incyte Announces Positive CHMP Opinion for Zynyz (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) Clinical Trial Results Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026 PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer Trial Initiation / Enrollment First Site Activated and First Patient Randomised in new brain cancer study VIGOR – EORTC‑2427‑BTG CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer Four additional sites open for recruitment in Oncoinvent’s Phase 2 trial Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor Preclinical New publication in Cell Death & Disease demonstrates the versatility and safety of Vartumab for cytotoxic payload delivery in oncology Preclinical Results of the Anti-CTLA-4 Switch Antibody ROSE12 Published in the Journal for ImmunoTherapy of Cancer ME THERAPEUTICS SCIETIFIC AND CORPORATE UPDATE Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2) Biomarker Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers Caris Life Sciences’ Real-World Data Uncovers Metastatic Breast Cancer Patient Responses and Resistance to Trastuzumab Deruxtecan GRAIL Submits FDA Premarket Approval Application for the Galleri Multi-Cancer Early Detection Test Patents Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors NUCLIDIUM Announces Issuance of New U.S. Patent Covering its 61Cu-based Radiodiagnostic Program for PSMA-positive Prostate Cancer Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer Abstract / Conference QureBio Ltd. to Present at ASCO (Free ASCO Whitepaper) 2026 its Q-1802 Phase II Clinical Results R&D Day / Investment Presentation Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 Other Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy

©2026 1stOncology™, a leading, award winning cancer intelligence service by BioSeeker Group AB This email was sent to you as part of the 1stOncologyWeekly™ email list which is administered by BioSeeker Group, Stockholm, Sweden. Please read our Privacy Policy to understand how we responsibly manage personal data. If the information in 1stOncologyWeekly is no longer of interest to you, Opt-out Here.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!